WEDGE: An anticoagulant thrombin mutant produced by autoactivation

D. C. Wood, L. A. Pelc, N. Pozzi, M. Wallisch, N. G. Verbout, Erik Tucker, Andras Gruber, Enrico Di Cera

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Summary: Background: The production of therapeutically relevant proteases typically involves activation of a zymogen precursor by external enzymes, which may raise regulatory issues about availability and purity. Recent studies of thrombin precursors have shown how to engineer constructs that spontaneously convert to the mature protease by autoactivation, without the need for external enzymes. Objectives: Autoactivation is an innovative strategy that promises to simplify the production of proteases of therapeutic relevance, but has not been tested in practical applications. The aim of this study was to provide a direct test of this strategy. Methods: An autoactivating version of the thrombin mutant W215A/E217A (WE), which is currently in preclinical development as an anticoagulant, was engineered. Results and Conclusions: The autoactivating version of WE can be produced in large quantities, like WE made in BHK cells or Escherichia coli, and retains all significant functional properties in vitro and in vivo. The results serve as proof of principle that autoactivation is an innovative and effective strategy for the production of trypsin-like proteases of therapeutic relevance.

Original languageEnglish (US)
Pages (from-to)111-114
Number of pages4
JournalJournal of Thrombosis and Haemostasis
Volume13
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Thrombin
Anticoagulants
Peptide Hydrolases
Enzyme Precursors
Trypsin
Escherichia coli
Enzymes
Therapeutics

Keywords

  • Anticoagulants
  • Blood coagulation factors
  • Protein engineering
  • Thrombin
  • Zymogens

ASJC Scopus subject areas

  • Hematology

Cite this

Wood, D. C., Pelc, L. A., Pozzi, N., Wallisch, M., Verbout, N. G., Tucker, E., ... Di Cera, E. (2015). WEDGE: An anticoagulant thrombin mutant produced by autoactivation. Journal of Thrombosis and Haemostasis, 13(1), 111-114. https://doi.org/10.1111/jth.12774

WEDGE : An anticoagulant thrombin mutant produced by autoactivation. / Wood, D. C.; Pelc, L. A.; Pozzi, N.; Wallisch, M.; Verbout, N. G.; Tucker, Erik; Gruber, Andras; Di Cera, Enrico.

In: Journal of Thrombosis and Haemostasis, Vol. 13, No. 1, 01.01.2015, p. 111-114.

Research output: Contribution to journalArticle

Wood, DC, Pelc, LA, Pozzi, N, Wallisch, M, Verbout, NG, Tucker, E, Gruber, A & Di Cera, E 2015, 'WEDGE: An anticoagulant thrombin mutant produced by autoactivation', Journal of Thrombosis and Haemostasis, vol. 13, no. 1, pp. 111-114. https://doi.org/10.1111/jth.12774
Wood, D. C. ; Pelc, L. A. ; Pozzi, N. ; Wallisch, M. ; Verbout, N. G. ; Tucker, Erik ; Gruber, Andras ; Di Cera, Enrico. / WEDGE : An anticoagulant thrombin mutant produced by autoactivation. In: Journal of Thrombosis and Haemostasis. 2015 ; Vol. 13, No. 1. pp. 111-114.
@article{fa28849dabe84f14816364dd266646aa,
title = "WEDGE: An anticoagulant thrombin mutant produced by autoactivation",
abstract = "Summary: Background: The production of therapeutically relevant proteases typically involves activation of a zymogen precursor by external enzymes, which may raise regulatory issues about availability and purity. Recent studies of thrombin precursors have shown how to engineer constructs that spontaneously convert to the mature protease by autoactivation, without the need for external enzymes. Objectives: Autoactivation is an innovative strategy that promises to simplify the production of proteases of therapeutic relevance, but has not been tested in practical applications. The aim of this study was to provide a direct test of this strategy. Methods: An autoactivating version of the thrombin mutant W215A/E217A (WE), which is currently in preclinical development as an anticoagulant, was engineered. Results and Conclusions: The autoactivating version of WE can be produced in large quantities, like WE made in BHK cells or Escherichia coli, and retains all significant functional properties in vitro and in vivo. The results serve as proof of principle that autoactivation is an innovative and effective strategy for the production of trypsin-like proteases of therapeutic relevance.",
keywords = "Anticoagulants, Blood coagulation factors, Protein engineering, Thrombin, Zymogens",
author = "Wood, {D. C.} and Pelc, {L. A.} and N. Pozzi and M. Wallisch and Verbout, {N. G.} and Erik Tucker and Andras Gruber and {Di Cera}, Enrico",
year = "2015",
month = "1",
day = "1",
doi = "10.1111/jth.12774",
language = "English (US)",
volume = "13",
pages = "111--114",
journal = "Journal of Thrombosis and Haemostasis",
issn = "1538-7933",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - WEDGE

T2 - An anticoagulant thrombin mutant produced by autoactivation

AU - Wood, D. C.

AU - Pelc, L. A.

AU - Pozzi, N.

AU - Wallisch, M.

AU - Verbout, N. G.

AU - Tucker, Erik

AU - Gruber, Andras

AU - Di Cera, Enrico

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Summary: Background: The production of therapeutically relevant proteases typically involves activation of a zymogen precursor by external enzymes, which may raise regulatory issues about availability and purity. Recent studies of thrombin precursors have shown how to engineer constructs that spontaneously convert to the mature protease by autoactivation, without the need for external enzymes. Objectives: Autoactivation is an innovative strategy that promises to simplify the production of proteases of therapeutic relevance, but has not been tested in practical applications. The aim of this study was to provide a direct test of this strategy. Methods: An autoactivating version of the thrombin mutant W215A/E217A (WE), which is currently in preclinical development as an anticoagulant, was engineered. Results and Conclusions: The autoactivating version of WE can be produced in large quantities, like WE made in BHK cells or Escherichia coli, and retains all significant functional properties in vitro and in vivo. The results serve as proof of principle that autoactivation is an innovative and effective strategy for the production of trypsin-like proteases of therapeutic relevance.

AB - Summary: Background: The production of therapeutically relevant proteases typically involves activation of a zymogen precursor by external enzymes, which may raise regulatory issues about availability and purity. Recent studies of thrombin precursors have shown how to engineer constructs that spontaneously convert to the mature protease by autoactivation, without the need for external enzymes. Objectives: Autoactivation is an innovative strategy that promises to simplify the production of proteases of therapeutic relevance, but has not been tested in practical applications. The aim of this study was to provide a direct test of this strategy. Methods: An autoactivating version of the thrombin mutant W215A/E217A (WE), which is currently in preclinical development as an anticoagulant, was engineered. Results and Conclusions: The autoactivating version of WE can be produced in large quantities, like WE made in BHK cells or Escherichia coli, and retains all significant functional properties in vitro and in vivo. The results serve as proof of principle that autoactivation is an innovative and effective strategy for the production of trypsin-like proteases of therapeutic relevance.

KW - Anticoagulants

KW - Blood coagulation factors

KW - Protein engineering

KW - Thrombin

KW - Zymogens

UR - http://www.scopus.com/inward/record.url?scp=84920993034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920993034&partnerID=8YFLogxK

U2 - 10.1111/jth.12774

DO - 10.1111/jth.12774

M3 - Article

C2 - 25369995

AN - SCOPUS:84920993034

VL - 13

SP - 111

EP - 114

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

SN - 1538-7933

IS - 1

ER -